AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.
AbbVie has successfully transitioned from Humira dependence to growth driven by Skyrizi and Rinvoq, while maintaining a 54-year dividend increase streak and expanding its pipeline to roughly 90 programs through strategic acquisitions.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07587008 |
Study to Assess Adverse Events and How Oral Emraclidine Moves Through the Body of Adult Healthy Volunteers |
ACTIVE_NOT_RECRUITING | PHASE1 |
